Health / WORLD

Australian report finds rising subsidised knee imaging rates among adults aged 45 and over

A national report compares Medicare subsidised imaging and hospitalisation rates. Its figures do not establish whether an individual scan was clinically justified.

Reading sizeSources ↓Share story ↗
Conceptual illustration of public health, research and connected data.Illustration
Symbolic illustration

The rate of publicly subsidised knee CT imaging among Australians aged 45 and over rose by 83 percent between the financial years 2019/20 and 2023/24, according to a national healthcare variation report published on 12 November 2026. The Australian Commission on Safety and Quality in Health Care says the findings can help identify potentially inappropriate care for knee osteoarthritis. The figures count imaging services, not the number of people who definitely received an unnecessary scan.

The commission's report examines Medicare Benefits Schedule subsidised knee imaging as well as hospitalisations for knee arthroscopy and knee replacement. Its measures are expressed as services or hospitalisations per 100,000 people in the specified age group. They describe trends in care across the population and do not establish the clinical reason for each individual scan or operation.

For knee CT, the report records 27,873 subsidised services in 2019/20 and 56,412 in 2023/24. The corresponding rates were 261 and 478 per 100,000 people aged 45 and older. Calculating the change from the published rates gives about 83 percent, matching the commission's rounded figure. The change in the number of services is a different calculation and should not be substituted for the rate change.

Other imaging rates increased over the same period, though by different amounts. The report states that subsidised knee ultrasound rose by 26 percent, X ray imaging by 10 percent and magnetic resonance imaging by 6 percent. These are national rate changes, not evidence that every type of imaging increased equally in every area. The report compares Australian states and territories, local areas, remoteness, socioeconomic disadvantage, age groups and the type of clinician requesting a service.

The imaging dataset has an important boundary. It does not include services paid entirely out of pocket by patients. The commission notes that out of pocket MRI may have increased after changes introduced in 2018 limited some general practitioner requests for subsidised knee MRI for patients aged 50 and over. Consequently, the reported Medicare figures should not be described as a complete count of all knee imaging in Australia.

The report uses a longer comparison for operations. Among people aged 45 and older, the national hospitalisation rate for knee arthroscopy fell by 50 percent between 2014/15 and 2023/24. The corresponding rate for knee replacement rose by 17 percent. In 2023/24 the report found a twelvefold geographic variation in arthroscopy rates and a sixfold variation for replacement. Those comparisons use different procedures and should not be treated as evidence that one operation caused a change in the other.

Regional differences also appear in imaging. For subsidised knee CT, the report found an eighteenfold difference between the local areas with the highest and lowest rates in 2023/24. Such variation can signal a need for further investigation, but the figures alone do not establish why local rates differ or whether a specific examination was clinically justified. Access to services and the people covered by each measure are important when interpreting the data.

The commission says knee osteoarthritis can usually be diagnosed through clinical assessment and that imaging is not usually required for that diagnosis. It also states that imaging may be needed when symptoms are atypical, another diagnosis is being considered or surgery is being planned. The distinction matters: a population level concern about imaging does not mean that every knee scan is inappropriate for every patient.

The report highlights education, support for self management and physical activity as components of initial care, with weight management or pain medicines where needed under relevant clinical guidance. It also calls for better access to recommended care before surgical referral. The analysis is a report on Australian healthcare patterns; it does not provide an individual diagnosis or replace a clinician's assessment of a particular patient's symptoms and circumstances.

Data

Timeline

Australian healthcare variation report published

The Australian Commission published its knee osteoarthritis report on 12 November 2026.

  1. · Occurred

    Australian healthcare variation report published

    The Australian Commission published its knee osteoarthritis report on 12 November 2026.

Methodology

The date is from the Commission report; figures describe subsidised services or hospitalisations and do not determine individual appropriateness.

Updated:

Table

Change in subsidised knee imaging rates

National changes between financial years 2019/20 and 2023/24, services per 100000 people aged 45 and over.

Computed tomography83
Ultrasound26
X ray10
Magnetic resonance imaging6
Methodology

Commission national rates of MBS subsidised knee imaging; services fully paid out of pocket are excluded. Rates cover knee imaging, not a verified count of unnecessary tests.

Updated:

Structured coverage

Subjects and places

Subject proposals

Geographic references

Only source-provided geographic references are shown. Opening an external map is optional. Optional story maps use OpenStreetMap. Opening a map sends your IP address and this site’s address to the map provider; location data remains readable as text without loading the map.

Taxonomy version: IPTC Media Topics 2026-Q2

Continue reading

Health

Australian report finds rising knee CT and ultrasound use as arthroscopy falls

A national Australian report found knee CT scans rose 83% and ultrasounds 26% over five years to 2023-24 among people aged 45 and older. Arthroscopy rates fell by half over a decade, while knee replacements rose 17%; the data describe service use, not proof that imaging caused surgery.

Australian Commission on Safety and Quality in Health Care, Atlas Focus Report: Osteoarthritis of the knee4 min read Data included
Health

Johnson & Johnson reports Phase 4 STAR trial gains for TREMFYA in axial psoriatic arthritis

Johnson & Johnson announced on 20 November 2026 that TREMFYA met primary and major secondary endpoints at Week 24 in the 411-patient Phase 4 STAR study of axial psoriatic arthritis, reducing BASDAI scores and MRI-assessed sacroiliac inflammation versus placebo.

Johnson & Johnson, Phase 4 STAR Study Results for TREMFYA in Axial Psoriatic Arthritis5 min read Data included